Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients

Launched by RABIN MEDICAL CENTER · Apr 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called Aprepitant to help manage itching, known as pruritus, in patients with solid tumors who are receiving certain cancer treatments called immune checkpoint inhibitors. Pruritus can be very uncomfortable and affect a person’s quality of life, especially when standard treatments don’t work. The trial aims to see if Aprepitant can effectively reduce this itching and improve the overall comfort of patients undergoing cancer treatment.

To participate in this study, you must be at least 18 years old and have a confirmed diagnosis of a solid tumor, such as melanoma or lung cancer, while currently receiving immune checkpoint inhibitors like nivolumab or pembrolizumab. Eligible participants should be experiencing new or persistent itching that hasn't responded to typical treatments. If you join this study, you’ll receive a specific dose of Aprepitant and will be monitored for any side effects and improvements in your itching. It’s important to note that individuals with certain allergies, severe skin conditions unrelated to cancer, or those pregnant or breastfeeding cannot participate. This study is currently not recruiting, but if you meet the criteria, it may be an option to consider in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years.
• • Histologically confirmed solid tumor (e.g., melanoma, RCC, NSCLC).
• • Currently receiving ICIs (such as but not limited to nivolumab, pembrolizumab, ipilimumab)
• * Pruritus that is either:
• • Refractory: Persistent pruritus despite standard treatment (e.g., antihistamines, corticosteroids).
• • New-onset: Developing after initiation of ICIs or targeted therapies.
• • ECOG performance status 0-2.
• • Willingness to comply with study procedures and provide informed consent.
• Exclusion Criteria:
• • History of severe allergic reactions to Aprepitant.
• • Uncontrolled or severe dermatologic conditions unrelated to cancer therapy.
• • Use of NK1R antagonists within 4 weeks before study entry.
• • Concurrent use of medications that strongly interact with Aprepitant.
• • Concurrent use of medications that may influence pruritus manifestation (e.g steroids or antihistamines) . Note, Regular treatment with such medications prior to the appearance of pruritus, and or pruritus appearing despite such regular treatment, will not disqualify you from participating in the study
• • Uncontrolled infection or significant comorbidities.
• • Pregnant or breastfeeding women.